Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
11/30/2016 12/01/2016 12/02/2016 12/05/2016 12/06/2016 Date
61.255(c) 60.185(c) 59.107(c) 59.881(c) 58.663 Last
35 5 500 0 200 0 Volume
-0.60% -1.75% -1.79% +1.31% -2.03% Change
More quotes
Financials (€)
Sales 2016 4 052 M
EBIT 2016 757 M
Net income 2016 467 M
Debt 2016 951 M
Yield 2016 2,07%
Sales 2017 4 342 M
EBIT 2017 911 M
Net income 2017 572 M
Debt 2017 615 M
Yield 2017 2,29%
P/E ratio 2016 22,56
P/E ratio 2017 18,47
EV / Sales2016 3,06x
EV / Sales2017 2,78x
Capitalization 11 437 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
03/03Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
11/17 UCB : Family Epilepsy Scholarship Program Announces 2016 Recipients
11/16 UCB : Juno Biomedical Moving Forward with Regenerative Stroke Treatment
11/15 UCB : The Lancet Publishes First Head-to-Head Study of Cimzia® (certolizumab peg..
11/11 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives positive opinion by EU C..
11/03 UCB : Patent Issued for Method for Producing Protein (USPTO 9476081)
10/25 UCB : continues its growth path
10/21 UCB : Transparency notification
10/10 UCB : Transparency notification
10/07 UCB : Transparency notification
10/03 UCB : CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpo..
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 77,4 €
Spread / Average Target 32%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA-30.58%12 285
JOHNSON & JOHNSON8.98%304 536
PFIZER INC.-2.14%191 699
ROCHE HOLDING LTD.-19.65%189 885
NOVARTIS AG-20.79%180 598
MERCK & CO., INC.15.73%166 118
More Results